doi:10.3760/cma.j.issn.1673-422X.2013.11.015

Abstract

Abstract: Treatment for locally advanced pancreatic cancerWANG Meng, YANG Jiyuan. Corresponding author:【Abstract】Combined therapy consisting of radiotherapy, chemotherapy and palliative surgery is the primary management for locally advanced pancreatic cancer, with the purpose of prolonging survival and improving life quality. Gemcitabine is the standard chemotherapy at present. Gemcitabinebased combinations show a definite effect, and the combination with targeted drugs also has a certain degree of efficacy. The development of new chemotherapy drugs and targeted drugs provides more ways for the teatment of locally advanced pancreatic cancer.

Key words: Pancreatic neoplasms, Drug therapy, Radiotherapy

WANG Meng, YANG Ji-Yuan. [J]. Journal of International Oncology, 2013, 40(11): 850-853.

References

［1］ Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet, 2011, 378(9791): 607-620．［2］ Ueno H, Okusaka T, Ikeda M, et al．A phase Ⅰ study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology, 2005, 69(5):421-427．［3］ Ueno H, Okusaka T, Furuse J, et al. Multicenter phase Ⅱ study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastaticpancreatic cancer. Jpn J Clin Oncol, 2011, 41(8):953-958．［4］ Sultana A, Tudur Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary endpoints analyses. Br J Cancer, 2008,99(1):6-13. ［5］ Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19):1817-1825．［6］ Peddi PF, Lubner S, McWilliams R, et al. Multiinstitutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP, 2012, 13(5):497-501．［7］ Cohen SJ, Dobelbower R Jr, Lipsitz S, et al. A randomized phase Ⅲ study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys, 2005, 62(5):1345-1350．［8］ Chauffert B, Mornex F, Bonnetain F, et al. Phase Ⅲ trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Ann Oncol, 2008, 19(9):1592-1599．［9］ Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus Gemcitabine plus Radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial. J Clin Oncol, 2011, 29(31):4105-4112．［10］ Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine based or capecitabine based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP):a multicentre, randomised, phase 2 trial. Lancet Oncol, 2013, 14(4):317-326．［11］ Shinchi H, Maemura K, Mataki Y, et al. A phase Ⅱ study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally　advanced pancreatic cancer．J Hepatobiliary Pancreat Sci, 2012, 19(2):152-158．［12］ Kim HM， Bang S， Park JY， et al． Phase Ⅱ trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.Cancer Chemother Pharmacol， 2009，63(3):535-541. ［13］ Shinchi H， Maemura K， Mataki Y， et al． A phase Ⅱ study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S1 alone for locally　advanced pancreatic cancer．J Hepatobiliary Pancreat Sci， 2012，19(2):152-158．［14］ Crane CH， Winter K， Regine WF， et al． Phase Ⅱ study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabineand bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411．J Clin Oncol， 2009，27(25):4096-4102．［15］ Xiong HQ， Rosenberg A， LoBuglio A， et al． Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase Ⅱ Trial. J Clin Oncol， 2004，22(13):2610-2616．［16］ Philip PA, Benedetti J, Corless CL, et al． Phase Ⅲ study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Groupdirected intergroup trial S0205. J Clin Oncol， 2010，28(22):3605-3610．［17］ Strumberg D， Schultheis B， Scheulen ME， et al． Phase Ⅱ study of nimotuzumab, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer． Invest New Drugs， 2012，30(3):1138-1143. ［18］ Strumberg D， Schultheis B， Scheulen ME， et al． Safety,efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody,in patients with locally advanced or metastatic pancreatic cancer． Int J Clin Pharmacol Ther， 2010，48(7):473-475．［19］ Crane CH, Mason K, Janjan NA, et al． Initial experience combining cyclooxygenase2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol， 2003，26(4)：S81-S84．［20］ Xiong HQ， Rosenberg A， LoBuglio A， et al. Cetuximab,a monoclonal antibody targeting the epidermal growth factor receptor, in combination withgemcitabine for advanced pancreatic cancer: a multicenter phase Ⅱ Trial．J Clin Oncol， 2004，22(13):2610-2616．［21］ Ferrari V， Valcamonico F， Amoroso V， et al． Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase Ⅱ trial. Cancer Chemother Pharmacol， 2006，57(2):185-190.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[14]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[15]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments